Quick Answer
FibroBiologics, Inc. reported Stockholders Equity of $6.16 million for fiscal year 2025.
FibroBiologics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.16M | +125.1% |
| 2024 | $2.73M | +118.3% |
| 2023 | $1.25M | +131.4% |
| 2022 | -$4.00M | -209.8% |
| 2021 | -$1.29M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $125.0K | -95.4% | -85.5% |
| June 30, 2025 | $860.0K | +136.0% | -63.4% |
| March 31, 2025 | $2.35M | +160.8% | -14.1% |
| December 31, 2024 | $2.73M | +118.3% | -0.1% |
| September 30, 2024 | $2.74M | -74.0% | +214.7% |
| June 30, 2024 | -$2.39M | -121.0% | +38.2% |
| March 31, 2024 | -$3.86M | -704.5% | -408.3% |
| December 31, 2023 | $1.25M | +131.4% | -88.1% |
- FibroBiologics, Inc. showed an increase of +125.1% in Stockholders Equity compared to the prior fiscal year.
- Over the 2021–2025 period, FibroBiologics, Inc.’s stockholders equity has grown by 577.2% (from -$1.29 million to $6.16 million).
- The most recent figure is from FibroBiologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: